Nav: Home

CF patients and physicians use shared decision-making tool to determine regimens

July 03, 2017

CINCINNATI--Physician-researchers at the University of Cincinnati have developed a computerized decision-making model to promote shared decision-making with cystic fibrosis patients. The tool takes into account patients' preferences for measures of lung function and health along with the latest medical evidence for effective treatment to help patients prioritize home treatments.

Mark Eckman, MD, Posey Professor of Clinical Medicine and director of the UC Division of General Internal Medicine, says a field study of 21 cystic fibrosis patients, ages 20 to 66, was performed to determine acceptability, understandability and ease of use.

"Patients found the tool easy to understand and felt engaged as active participants in their care," says Eckman, the study's lead author, who is also a UC Health physician. "The tool was responsive to variations in patient preferences."

The study is now available in the scholarly journal Medical Decision Making Policy & Practice.

Cystic Fibrosis (CF) is a progressive, genetic disease that causes persistent lung infections and limits the ability to breathe over time, according to the Cystic Fibrosis Foundation. A defective gene causes a thick buildup of mucus in the lungs, pancreas and other organs. More than 30,000 people in the United States are living with the disease. Individuals affected have median life expectancy of 40.7 years.

Participants in the study were asked what they considered the most important goals of home therapy for treating CF and once determined they were asked to rate on a scale of one to nine the following options: preventing lung infection, improving breathing function, improving functionality and feeling of well-being, minimizing time required daily to complete all treatments and interventions and minimizing cost.

Researchers also determined which home treatment alternatives were considered the most important based on medical and scientific literature and input from patients. They complied the following list: inhaled dornase alfa, inhaled antibiotics, inhaled hypertonic saline, airway clearance and exercise. Again, patients were given a chance to rank their preferences of treatments.

Patricia Joseph, MD, director of the Adult Cystic Fibrosis Program at UC Medical Center, says CF patients on average spend anywhere from 1 ½ to 2 hours each day completing home therapies.

"When therapies come up we discuss risks and benefits and I have a lot of patients say 'Yeah, but I am not doing that.' They say, 'I don't like the drug, it makes me wheezy' or 'Exercise, it takes too much time and doesn't really help me very much," says Joseph, a co-author in the study.

"What this tool does that is different is that it takes their preferences and their personal experiences with the therapies along with their personal goals for care and integrates them to help prioritize their own home care plan which therapies best fit their personal goals," explains Joseph, who is also a professor in the UC Division of Pulmonary, Critical Care and Sleep Medicine.

Some patients can't always do all of the home therapies each day. "We are asking them to do therapies they may not feel are beneficial," says Joseph. "The tool gets their preferences and values and helps them prioritize their best home treatment plan."

Personalized data for a patient's goals and treatment preferences are entered into a computational framework known as the Analytic Hierarchy Process (AHP). The system assigns weights to these preferences and combines them with quantitative data on treatment efficacy, costs and time estimates to come up with a score for each of the treatment alternatives, explains Eckman.

Currently, the analytic system uses a Microsoft Excel spreadsheet model but Eckman says he hopes to make the tool available via an electronic tablet patients can use to input their own data and tabulate results immediately so physicians and patients can discuss these on the same day. Right now patient information is entered via paper surveys and then transferred to the computer model.

Eckman says the next step is to perform a randomized clinical trial to evaluate the impact doctor visits facilitated by the CF-Shared Decision Making Tool compared to visits that don't employ this technique.
-end-
Other co-authors of the study include Elizabeth Kopras, Karen Montag-Leifling, Lari Kirby, and Lisa Burns, MD, assistant professor in the Department of Pediatrics, along with Veronica Indihar, MD, assistant professor in the Department of Internal Medicine.

Support for this study came from the Cystic Fibrosis Foundation Grant Number 15Q10 and National Institutes of Health/NCATS Grant Number 1UL1TR001425-01. The funding sources had no role in the planning, design, or conduct of this study or the writing of this report.

University of Cincinnati Academic Health Center

Related Cystic Fibrosis Articles:

Cystic fibrosis: why so many respiratory complications?
Cystic fibrosis, one of the most common genetic diseases in Switzerland, causes severe respiratory and digestive disorders.
A newly discovered disease may lead to better treatment of cystic fibrosis
Cystic fibrosis is the most frequent severe inherited disorder worldwide.
New treatment kills off infection that can be deadly to cystic fibrosis patients
The findings, which are published in the journal Scientific Reports, show that scientists from Aston University, Mycobacterial Research Group, combined doses of three antibiotics -- amoxicillin and imipenem-relebactam and found it was 100% effective in killing off the infection which is usually extremely difficult to treat in patients with cystic fibrosis.
Cystic fibrosis carriers are at increased risk for cystic fibrosis-related conditions
A University of Iowa study challenges the conventional wisdom that having just one mutated copy of the cystic fibrosis (CF) gene has no effects on a person's health.
Modifier gene may explain why some with cystic fibrosis are less prone to infection
People with cystic fibrosis who carry genetic variants that lower RNF5 gene expression have more mutant CFTR protein on cell surfaces.
Rare mutations drive cystic fibrosis in Caribbean
Cystic Fibrosis (CF) in the Caribbean is dominated by unusual gene mutations not often observed in previously studied CF populations, according to comprehensive genome sequencing led by physician-scientists at UC San Francisco and Centro de Neumología Pediátrica in San Juan.
Cystic fibrosis carriers at increased risk of digestive symptoms
Researchers have found that carriers of the most common genetic variant that causes cystic fibrosis experience some symptoms similar to those of people with cystic fibrosis.
In cystic fibrosis, lungs feed deadly bacteria
A steady supply of its favorite food helps a deadly bacterium thrive in the lungs of people with cystic fibrosis, according to a new study by Columbia researchers.
Cibio knocks out cystic fibrosis
The fight against cystic fibrosis continues, targeting in particular some of the mutations that cause it.
Hypertonic saline may help babies with cystic fibrosis breathe better
Babies with cystic fibrosis may breathe better by inhaling hypertonic saline, according to a randomized controlled trial conducted in Germany and published in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.
More Cystic Fibrosis News and Cystic Fibrosis Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Power Of Spaces
How do spaces shape the human experience? In what ways do our rooms, homes, and buildings give us meaning and purpose? This hour, TED speakers explore the power of the spaces we make and inhabit. Guests include architect Michael Murphy, musician David Byrne, artist Es Devlin, and architect Siamak Hariri.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at Radiolab.org/donate.     You can read The Transition Integrity Project's report here.